<DOC>
	<DOCNO>NCT00053989</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving immunosuppressive therapy transplant may stop happen . PURPOSE : This phase II trial study well chemotherapy follow donor peripheral stem cell transplant work treat patient hematologic cancer aplastic anemia .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplant Treating Patients With Hematologic Cancer Aplastic Anemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxic effect nonmyeloablative allogeneic peripheral blood stem cell transplantation patient hematologic malignancy aplastic anemia . - Determine clinical response overall outcome patient treat regimen . - Determine incidence graft-vs-tumor effect , graft-vs-host disease , chimerism patient treat regimen . OUTLINE : - Preparative regimen : - Matched relate unrelated donor transplantation : - Patients receive cyclophosphamide IV 2 hour day -5 -4 fludarabine IV 30 minute day -5 -1 . - Cord blood transplantation : - Patients receive regimen plus anti-thymocyte globulin IV 4 hour day -3 -1 . - Graft-vs-host disease ( GVHD ) prophylaxis : - Matched relate unrelated donor transplantation : - Patients receive oral tacrolimus ( IV ) daily oral mycophenolate mofetil ( MMF ) ( IV ) twice daily day -1 60 follow tapering* regimen . Patients receive methotrexate IV day 1 , 3 , 6 . NOTE : *This regimen taper day 30-60 donor chimerism T-cells 100 % . MMF stop tacrolimus tapered 25 % every 10 day discontinue day 90 GVHD develops . - Cord blood transplantation : - Patients receive tacrolimus MMF regimen plus methylprednisolone twice daily day 1-19 blood count recover . - Allogeneic stem cell reinfusion : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously daily begin day 7 continue blood count recover . - Donor lymphocyte infusion ( DLI ) : Patients convert 100 % donor T-cell chimerism day 120 showing sign progresson disease tacrolimus MMF withdrawal may receive DLI every 8 week 3 infusion . Cord blood recipient receive DLI . Patients follow day 100-120 , every 3 month 2 year , every 6 month 5 year . PROJECTED ACCRUAL : A total 30-60 patient accrue study within 6-7 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis aplastic anemia Severe disease Failed least 1 course standard immunosuppressive regimen cyclosporine antithymocyte globulin OR Histologically confirm hematologic malignancy include follow : Acute leukemia Any follow type : Acute myeloid leukemia ( AML ) antecedent myelodysplastic syndrome Secondary AML AML highrisk cytogenetic abnormality Acute lymphoblastic leukemia highrisk cytogenetic abnormality Resistant recurrent disease combination chemotherapy least 1 standard regimen OR In first remission high risk relapse Chronic myelogenous leukemia Chronic phase meeting least 1 follow criterion : Failed imatinib mesylate Failed interferon least 6 month treatment minimum 21 million unit interferon per week Unable tolerate interferon Accelerated phase ( blast less 20 % ) Myeloproliferative myelodysplastic syndrome Myelofibrosis ( splenectomy ) Refractory anemia Refractory anemia excess blast Chronic myelomonocytic leukemia Lymphoproliferative disease Chronic lymphocytic leukemia Symptomatic disease firstline chemotherapy Lowgrade nonHodgkin 's lymphoma ( recurrent persistent ) Symptomatic disease firstline chemotherapy Multiple myeloma Progressive disease autologous stem cell transplantation Waldenstrom 's macroglobulinemia Failed 1 standard regimen NonHodgkin 's lymphoma meeting follow criterion : Intermediate high grade Controlled chemosensitive disease First remission lymphoblastic small noncleaved cell lymphoma high risk relapse Hodgkin 's lymphoma Relapsed chemosensitive disease Not eligible standard myeloablative allogeneic stem cell transplantation Availability follow donor type : Related donor match 5 6 HLA antigen ( A , B , DR ) Unrelated donor fully match molecular analysis A , B , DRB1 , DQB1 loci Single antigen mismatch C allow Cord blood 4 , 5 , 6 match recipient HLA antigens ( A , B , DR ) NOTE : No syngeneic donor permit No uncontrolled CNS disease ( hematologic malignancy ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 5 75 ( relate donor transplantation ) 5 60 ( unrelated donor transplantation ) Performance status Karnofsky &gt; 50 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin less 3 time normal Alkaline phosphatase less 3 time normal AST/ALT le 3 time normal No Child 's class B C liver failure Renal Creatinine clearance great 40 mL/min Cardiovascular Cardiac ventricular ejection fraction least 35 % MUGA No cardiovascular disease Pulmonary DLCO least 40 % predict , correct hemoglobin and/or alveolar ventilation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV antibody negative No uncontrolled diabetes mellitus No active serious infection No disease would preclude study therapy No concurrent malignancy except nonmelanoma skin cancer No concurrent serious psychiatric illness PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 6 month since prior autologous bone marrow transplantation ( BMT ) At least 12 month since prior allogeneic BMT Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy Surgery At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>grade 1 follicular lymphoma</keyword>
	<keyword>grade 2 follicular lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>